Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00301119
Status:
RECRUITING
Last Update Posted:
2023-10-25
First Post:
2006-03-08
Brief Title:
Lung Cancer Biomarkers and Screening
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
NYU Lung Cancer Biomarker Center
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NYULCBC
Brief Summary:
RATIONALE Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer
PURPOSE This clinical trial is studying biomarkers in screening participants for lung cancer
PURPOSE This clinical trial is studying biomarkers in screening participants for lung cancer
Detailed Description:
OBJECTIVES
Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers
Identify preneoplastic cellular changes and lesions in these patients
OUTLINE Participants are stratified according to lung cancer risk status with or without increased risk
Group 1 screening cohort Participants complete a questionnaire and undergo pulmonary function testing multidetector chest CT scan sputum induction and phlebotomy
Group 2 rule-out lung cancer Participants complete the same questionnaire and undergo the same tests and scans as in group 1 Some participants may undergo fiberoptic bronchoscopy based upon CT scan results with transbronchial or endobronchial biopsies Some participants may undergo lung resection Tissue samples are collected from surgery or biopsy
PROJECTED ACCRUAL A total of participants will be accrued for this study
Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers
Identify preneoplastic cellular changes and lesions in these patients
OUTLINE Participants are stratified according to lung cancer risk status with or without increased risk
Group 1 screening cohort Participants complete a questionnaire and undergo pulmonary function testing multidetector chest CT scan sputum induction and phlebotomy
Group 2 rule-out lung cancer Participants complete the same questionnaire and undergo the same tests and scans as in group 1 Some participants may undergo fiberoptic bronchoscopy based upon CT scan results with transbronchial or endobronchial biopsies Some participants may undergo lung resection Tissue samples are collected from surgery or biopsy
PROJECTED ACCRUAL A total of participants will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NYU-H-8896-06-B | None | None | None |